859721-53-2

Basic information

• Product Name: 4-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-2-AMINE
• Synonyms: 4-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-2-AMINE;4-(4-(Trifluoromethyl)phenyl)oxazol-2-amino;4-[4-(trifluoromethyl)phenyl]-2-Oxazolamine
• CAS NO: 859721-53-2
• Molecular Formula: C10H7F3N2O
• Molecular Weight: 228.1705896
• Mol File: 859721-53-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 321.367°C at 760 mmHg
• Flash Point: 148.158°C
• Appearance: /
• Density: 1.37g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.518
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-2-AMINE(859721-53-2)
• EPA Substance Registry System: 4-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-2-AMINE(859721-53-2)

Safety Data

• Hazardous Substances Data: 859721-53-2(Hazardous Substances Data)

Usage

General Description

4-(4-(Trifluoromethyl)phenyl)oxazol-2-amine is a chemical compound with the molecular formula C10H7F3N2O. It is a member of the oxazole class of compounds, which are heterocyclic aromatic organic compounds containing a five-membered ring with oxygen and nitrogen atoms. This particular compound contains a trifluoromethyl group, which is a functional group consisting of three fluorine atoms bonded to a single carbon atom. Oxazol-2-amine derivatives have been studied for their potential pharmacological properties, including as anti-inflammatory and anti-cancer agents. The trifluoromethyl substituent on this compound may also confer unique reactivity and properties, making it of interest in the development of new materials and pharmaceuticals.

InChI:InChI=1/C10H7F3N2O/c11-10(12,13)7-3-1-6(2-4-7)8-5-16-9(14)15-8/h1-5H,(H2,14,15)

Upstream product

• 383-53-9 2-bromo-1-[4-(trifluoromethyl)phenyl]ethanone 
• 57-13-6 urea 

Relevant articles and documents

INHIBITOR COMPOUNDS

The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.

Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3)

Transient receptor potential vanilloid type 3 (TRPV3) is a Ca2+ permeable nonselective cation channel and expressed abundantly in skin keratinocytes. TRPV3 emerges as an attractive target for treatment of pruritic, inflammatory, pain and skin-related diseases. However, only a few reports of TRPV3 inhibitors exist at present besides some patents. Therefore, TRPV3 research has always been fraught with challenges. Through a combination of virtual screening and biological evaluation, compound P1 (10 μM) was identified as a top hit with 34.5% inhibitory effect on 2-APB (1 mM)-evoked currents of mTRPV3-WT. Further structural optimization provided the inhibitor PC5 with the best activity (IC50 = 2.63 ± 0.28 μM), and point mutation assays indicated that amino acids V629 and F633 are crucial for the binding of PC5 and TRPV3. In summary, these newly discovered inhibitors could serve as promising lead compounds for the development of TRPV3 inhibitors in the future.